Literature DB >> 7674317

The use of gene tests to detect hereditary predisposition to cancer: economic considerations.

M L Brown1, L G Kessler.   

Abstract

Several mutations recently have been shown to be associated with hereditary nonpolyposis colon cancer (HNPCC) in families displaying unusually strong predisposition to colorectal cancer. Laboratory tests to detect such gene mutations soon will be commercially available, raising the possibility for population-wide screening. The purpose of this study was to explore the economic implications of conducting a population-wide screening for HNPCC compared with restricted screening among members of the families at high risk. An exploratory analysis was performed to determine which factors are most important in determining the cost-effectiveness of such a testing program. The base-case analysis focuses on current uncertainty about the population prevalence of the HNPCC genotype and phenotype. The uncertainty with regard to parameters related to the cost-effectiveness of screening and preventive interventions for HNPCC were explored, using additional sensitivity analyses. Cost-effectiveness is achieved for population-wide screening only when assumptions most favorable to that outcome are made regarding the HNPCC prevalence, the cost and effectiveness of screening, and preventive intervention. Information on the population prevalence of HNPCC genotypes and the penetrance of these genotypes is essential for making policy decisions. Additional information is needed regarding the determinants of the cost of genetic testing and counseling, the efficacy of preventive regimens for individuals at high risk, and the accuracy and cost of alternative methods of identifying families at risk.

Entities:  

Mesh:

Year:  1995        PMID: 7674317     DOI: 10.1093/jnci/87.15.1131

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

Review 1.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

2.  Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis.

Authors:  Scott D Ramsey; Wylie Burke; Linda Pinsky; Lauren Clarke; Polly Newcomb; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-11       Impact factor: 4.254

3.  A History of Health Economics and Healthcare Delivery Research at the National Cancer Institute.

Authors:  V Paul Doria-Rose; Nancy Breen; Martin L Brown; Eric J Feuer; Ann M Geiger; Larry Kessler; Joseph Lipscomb; Joan L Warren; K Robin Yabroff
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

Review 4.  Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer.

Authors:  Alberto Redaelli; Carole W Cranor; Gary J Okano; Pat Ray Reese
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer.

Authors:  Scott D Ramsey; Wylie Burke; Lauren Clarke
Journal:  Genet Med       Date:  2003 Sep-Oct       Impact factor: 8.822

6.  A micro costing of NHS cancer genetic services.

Authors:  G L Griffith; R Tudor-Edwards; J Gray; R Butler; C Wilkinson; J Turner; B France; P Bennett
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

Review 7.  Population Based Testing for Primary Prevention: A Systematic Review.

Authors:  Ranjit Manchanda; Faiza Gaba
Journal:  Cancers (Basel)       Date:  2018-11-05       Impact factor: 6.639

Review 8.  Cancer genetics services: a systematic review of the economic evidence and issues.

Authors:  G L Griffith; R T Edwards; J Gray
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

9.  Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.

Authors:  Marco Di Marco; Elvira DAndrea; Nikola Panic; Valentina Baccolini; Giuseppe Migliara; Carolina Marzuillo; Corrado De Vito; Roberta Pastorino; Stefania Boccia; Paolo Villari
Journal:  Genet Med       Date:  2018-01-04       Impact factor: 8.822

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.